113 related articles for article (PubMed ID: 9015912)
21. [Effectiveness of lithium in the prophylaxis of affective disorders].
Ezquiaga E; García-López A; Nieves P; Rodríguez-Salvanés F
Actas Esp Psiquiatr; 2000; 28(3):156-60. PubMed ID: 11000697
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of the psychotropic action of lithium and carbamazepine.
Rybakowski J
Pharmacol Toxicol; 1992; 71 Suppl 1():30-41. PubMed ID: 1480559
[No Abstract] [Full Text] [Related]
23. Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders.
Mann K; Hiemke C; Lotz J; Schmidt LG; Lackner KJ; Bates DW
J Clin Psychopharmacol; 2006 Dec; 26(6):671-3. PubMed ID: 17110832
[No Abstract] [Full Text] [Related]
24. [Prophylactic long-term therapy of affective disorders with lithium, valproic acid and carbamazepine--effectiveness and cost-effectiveness].
Roick C; Ahrens B; Becker T
Psychiatr Prax; 2001 Jul; 28 Suppl 1():S32-40. PubMed ID: 11533905
[TBL] [Abstract][Full Text] [Related]
25. [Investigation on the therapeutic effect of carbamazepine on the mood disorders in Japan].
Okuma T
Seishin Shinkeigaku Zasshi; 2005; 107(5):415-22. PubMed ID: 15981617
[TBL] [Abstract][Full Text] [Related]
26. Appropriateness of therapeutic drug monitoring for lithium.
Ratanajamit C; Soorapan S; Doang-ngern T; Waenwaisart W; Suwanchavalit L; Suwansiri S; Jantasaro S; Yanate I
J Med Assoc Thai; 2006 Nov; 89(11):1954-60. PubMed ID: 17205880
[TBL] [Abstract][Full Text] [Related]
27. Lithium carbonate: maintenance studies and consequences of withdrawal.
Dunner DL
J Clin Psychiatry; 1998; 59 Suppl 6():48-55; discussion 56. PubMed ID: 9674937
[TBL] [Abstract][Full Text] [Related]
28. The use of ion-selective electrodes for evaluating residence time distributions in expanded bed adsorption systems.
Fernández-Lahore HM; Lin DQ; Hubbuch JJ; Kula MR; Thömmes J
Biotechnol Prog; 2001; 17(6):1128-36. PubMed ID: 11735451
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of lithium in patients treated with controlled release lithium formulations.
Phillips JD; Myers DH; King JR; Armond AD; Derham C; Puranik A; Corbett JA; Birch NJ
Int Clin Psychopharmacol; 1990 Jan; 5(1):65-9. PubMed ID: 2332609
[TBL] [Abstract][Full Text] [Related]
30. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
Manji HK; Bebchuk JM; Moore GJ; Glitz D; Hasanat KA; Chen G
J Clin Psychiatry; 1999; 60 Suppl 2():27-39; discussion 40-1, 113-6. PubMed ID: 10073385
[TBL] [Abstract][Full Text] [Related]
31. [Lithium: principles and rules of use].
Pinabel F; Hardy P
Rev Prat; 1999 Nov; 49(18):2053-9. PubMed ID: 10626495
[No Abstract] [Full Text] [Related]
32. Comparison of vitros dry slide technology for determination of lithium ions with other methods.
Serdarević N; Malesić I; Kozjek F
Bosn J Basic Med Sci; 2006 May; 6(2):32-6. PubMed ID: 16879110
[TBL] [Abstract][Full Text] [Related]
33. [Flame photometry determination of serum lithium. Routine method for the supervision of lithium therapy in psychiatry].
Doerr P; Stamm D
Z Klin Chem Klin Biochem; 1968 May; 6(3):178-82. PubMed ID: 5709558
[No Abstract] [Full Text] [Related]
34. Cognitive and affective functions in patients with affective disorders treated with lithium. An assessment by questionnaire.
Kjellman BF; Karlberg BE; Thorell LH
Acta Psychiatr Scand; 1980 Jul; 62(1):32-46. PubMed ID: 7446191
[TBL] [Abstract][Full Text] [Related]
35. [Mechanism and clinical effects of drugs for mood disorder].
Nakagawa S; Koyama T
Ryoikibetsu Shokogun Shirizu; 2003; (38):358-61. PubMed ID: 12877002
[No Abstract] [Full Text] [Related]
36. The medical use of lithium.
Birch NJ
Met Ions Biol Syst; 2004; 41():305-32. PubMed ID: 15206121
[No Abstract] [Full Text] [Related]
37. Affective disorders & "chemical dependence": lithium for alcohol and drug addiction? A clinical note.
Flemenbaum A
Dis Nerv Syst; 1974 Jun; 35(6):281-5. PubMed ID: 17894301
[TBL] [Abstract][Full Text] [Related]
38. [Drug therapy for patients with mood disorders].
Nomura S
Seishin Shinkeigaku Zasshi; 2001; 103(12):1041-5. PubMed ID: 11925842
[No Abstract] [Full Text] [Related]
39. The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders.
Gray NA; Zhou R; Du J; Moore GJ; Manji HK
J Clin Psychiatry; 2003; 64 Suppl 5():3-17. PubMed ID: 12720479
[TBL] [Abstract][Full Text] [Related]
40. Introduction: the use of mood stabilizers in the treatment of psychiatric disorders.
Bowden CL
J Clin Psychiatry; 1999; 60 Suppl 5():3-4. PubMed ID: 10192401
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
